There is a clear need to develop new approaches in the fight against Alzheimer’s Disease.
Current treatment options have little impact on the life of the patient, or the two-to-four unpaid caregivers each patient needs to care for them.
Cerebain has the critical intellectual property, management and development experience and expertise, the passion and the drive to put its clinical and regulatory strategies in place and execute against them.
Our vision: Forge a new and more effective path forward in this fight against a killer that robs every victim of past and future.
-Now is the time-
This website contains certain “forward-looking statements.”
Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.
Private Transaction: If you are considering acquiring shares of Cerebain Biotech Corp. in a private transaction directly from a third party you should verify the validity of the shares you are considering purchasing prior to paying any money to acquire the shares. Cerebain Biotech Corp. is happy to assist you with this process. If you would like the Company’s assistance, please have the proposed seller send you a copy of the stock certificate evidencing the shares of Cerebain Biotech Corp. (fka Discount Dental Materials, Inc.) he or she holds and then send that copy to Investor Relations at firstname.lastname@example.org. The Company’s management will then confirm with the Company’s transfer agent that the shareholder and share certificate appear on the Company’s official shareholder list and let you know. You should also ask the proposed seller how they acquired the shares, whether it was directly from the Company or from a third party and you should ask to see evidence of how they acquired the shares. Please let the Company know if you have any questions.
Directly from Cerebain Biotech Corp.: If you are considering acquiring shares of Cerebain Biotech Corp. from someone claiming to represent Cerebain Biotech Corp., and that person is not a member of Cerebain Biotech Corp.’s executive management team, please confirm directly with a member of Cerebain Biotech Corp.’s executive management that the person has authority to speak on behalf of, and bind, Cerebain Biotech Corp.
Cerebain Biotech Engages NMS Capital Advisors
Cerebain Biotech Corp. a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device to address dementias, and in particular, Alzheimer’s disease, today announced that the Company has engaged NMS Capital Advisors, LLC as its financial advisor.
Cerebain Biotech Engages Biotechnical Engineer
Cerebain Biotech today announced that the company has engaged a Biotechnical Engineer to serve on the corporate team. The engagement comes as Cerebain readies itself for clinical trials and the FDA application process in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia.
Cerebain Biotech Applauds Congressional Passage of 21st Century Cures Act
Cerebain Biotech today applauded the Congressional passage of the 21st Century Cures Act. The law has the potential to invigorate medical research, promote innovation and speed the development of new treatments for Alzheimer’s and other chronic diseases.
Cerebain Biotech Presents Update on its Medical Device Research and Development as it Continues its Battle Against Alzheimer’s and Dementia
Cerebain Biotech today announced that the executive team of Cerebain Biotech Corp. is very pleased to provide an update on the progress of its medical device research and development made over the last year and an outlook of 2017.
Cerebain Biotech and Mossakowski Medical Research Centre Sign Memorandum of Understanding
Cerebain Biotech today announced that they signed a Memorandum of Understanding with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland.
Governor Scott McCallum, Representing Cerebain Biotech, to Present at US-Poland Health Care Summit
Cerebain Biotech today announced that Governor Scott McCallum, former governor of Wisconsin, has received an invitation and will be participating in a US-Poland Health Care Summit.
Cerebain Biotech Announces Business Relocation into the Heart of Orange County, California
Cerebain Biotech today announced that it is relocating its corporate headquarters into the heart of Orange County in Costa Mesa, California.
Cerebain Biotech Announced it Plans to Seek FDA Approval
Cerebain Biotech announced that the company plans to seek FDA approval in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia.
Cerebain Biotech Appoints Dr. Azad L. Sheikh to Scientific Advisory Board
Cerebain Biotech today announced that the company has appointed Azad L. Sheikh, MBBS, MRCP (UK), FRCP (C), MBA, to its Scientific Advisory Board.
Cerebain Biotech Announces the Appointment of NFL Legend to Chair Sports Awareness Committee
Cerebain Biotech (OTCQB: CBBT) today announced the appointment of Richmond Webb to chair their Sports Awareness Committee.
Cerebain Biotech Presents Corporate Update on its War Against Alzeimer’s and Dementia
Cerebain Biotech’s Executive Team provides an update on the progress made over the last year and an outlook of 2016
Cerebain Biotech to Present at Polish National Center for Research & Development
Cerebain Biotech has received an invitation from the Polish National Center for Research and Development to present to a Poland-US Workshop
Cerebain Biotech Receives Financial Commitment of Two Million Dollars
Alzheimer’s Disease Research Company receives $2,000,000 financial commitment which enable it to rapidly advance corporate development
Scott McCallum, Former Wisconsin Governor, Engaged by Cerebain Biotech as Special Advisor
Governor McCallum to lend business and finance expertise to Alzheimer’s company poised to evaluate novel treatment for Alzheimer’s Disease
Cerebain Biotech Appoints Mustafa Husain, M.D., to Scientific Advisory Board
Preeminent Neuropsychiatry Physician Joins Scientific Advisory Board of Alzheimer’s Disease R&D Company